It's a flop: Gilead's top late-stage drug selonsertib flunked its first Phase III NASH trial
Gilead’s high profile STELLAR-4 study of its top late-stage NASH drug selonsertib has hit the finish line, and it’s starting out Phase III results with a big-time failure.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.